Legacies of eugenics: confronting the past, forging a future
By Marius Turda,
Ethnic and Racial Studies
| 07. 20. 2022
After 1900, eugenics became an influential scientific theory used by physicians, health experts, religious leaders and politicians across the political spectrum to express their understanding of human and social evolution and formulate their duties and responsibilities towards the nation, the race, and future generations. Physical and intellectual achievements, it was assumed, were determined by heredity. To control heredity, eugenicists claimed, was to ensure the betterment of future generations and the survival of the species. Another popular claim put forward during the first half of the twentieth century was that modern society was under constant threat from those with physical and mental disabilities (Stern 2016; Herzog 2018). Eugenicists wanted to prevent these people from having children. Protecting the so-called “feebleminded”, the constitutionally weak and the socially “unfit” was deemed detrimental to the future of the race. Finally, eugenics promised a solution to social problems as varied as crime, alcoholism, and poverty. None of these claims were substantiated by credible scientific evidence, but this did not prevent the application of eugenics on social, economic, and racial grounds. Throughout the twentieth...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...